MicroRNA Applications in Gestational Diabetes Management

Gestational diabetes mellitus (GDM) is a common pregnancy complication marked by glucose intolerance and rising risks for both mother and child. MicroRNAs (miRNAs), short non-coding RNAs that fine-tune gene expression, have emerged as pivotal regulators of pathways governing insulin sensitivity, glucose metabolism and inflammatory responses in GDM. Aberrant miRNA profiles in placental tissue, maternal circulation and fetal compartments reflect dynamic epigenetic interactions and tissue crosstalk. These small regulators offer multiple applications: as early non-invasive biomarkers for risk stratification, as mechanistic probes into β-cell function and placental nutrient transport, and as therapeutic agents or targets to restore metabolic homeostasis. Integration of miRNA panels with clinical parameters promises improved prediction, personalised monitoring and novel interventions in global GDM management.

Research from Nature Portfolio

Recent studies have revealed that up-regulation of miR-98 in placental tissues from GDM pregnancies drives global DNA hypermethylation by targeting a methyl-CpG binding protein, thereby disrupting expression of glucose uptake genes. This work unveils an epigenetic mechanism linking miRNA dysregulation to altered nutrient transport at the maternal–foetal interface. In parallel, investigations into whole blood cell miRNAs have shown that miRNA-340 levels rise in mothers with GDM and are inversely regulated by insulin and glucose in vitro. These findings highlight an insulin-induced epigenetic programming of maternal immune cells and point to miRNA-340 as a candidate marker of systemic metabolic adaptation during GDM.

MicroRNA Applications in Gestational Diabetes Management publication trend

The graph below shows the total number of articles in microrna applications in gestational diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

MicroRNA (miRNA): Small non-coding RNA molecules (~21–25 nucleotides) that regulate gene expression by binding target mRNAs.

Gestational diabetes mellitus (GDM): Glucose intolerance first recognised during pregnancy, with implications for maternal and neonatal health.

Epigenetic regulation: Heritable modification of gene expression without changing the DNA sequence, including DNA methylation and histone modification.

DNA methylation: Addition of methyl groups to DNA, often at CpG sites, influencing gene transcription and chromatin structure.

Oral glucose tolerance test (OGTT): Clinical assessment measuring blood glucose response over time following a standard glucose load, used to diagnose GDM.

References

1. Up-regulation of miR-98 and unraveling regulatory mechanisms in gestational diabetes mellitus. Scientific Reports (2016).
2. Maternal whole blood cell miRNA-340 is elevated in gestational diabetes and inversely regulated by glucose and insulin. Scientific Reports (2018).
3. Exploring the potential of microRNA as a diagnostic tool for gestational diabetes. Journal of Translational Medicine (2023).
4. Circulating microRNA as Biomarkers for Gestational Diabetes Mellitus—A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences (2023).
5. First-Trimester Plasmatic microRNAs Are Associated with Fasting Glucose Levels in Late Second Trimester of Pregnancy. Biomedicines (2024).